Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by jimmyhorizonon Sep 07, 2022 4:07pm
76 Views
Post# 34947745

RE:Howard

RE:Howard
PeterG wrote:
biorun, this would again an excuse for Sirona and especially for the part time CEO Howard Verrico!!! Why are they not communicate clear and loudly?? So why do we always see ways of Missinterpretation??? The pet deal was due almost two years ago. Remember the words back in December 2020. We are very close but due to the holiday vacation we can't guarantee an announcement this year!! This was loud and clear communicated!! It's time for a step change and the missing trade volume over the course of the recent month's ( although having fantastic news) are my interpretation of losing trust in the CEO! Only hard facts count...! As Howard is the biggest shareholder, he needs to change the way how to operate and communicate!!!


because it's their business model.

1. issue a few million warrants at 0.16

2. drive the price up with misleading statements through interviews, biorun's posts on stockhouse or reports from prc partners

3. sell until the price is just above the exercise price of the warrants (around 0.18). the fraud is outsourced and they are in desperatly need of money

4. then the real results (which can hold at most 1/10 of what was promised) are kept secret as long as possible

5. biorun then starts to slowly lower the stoked expectations again and adjust them to reality

6. inventing a new fairytale. now we reverse the age process. that’s really exciting.

or is there another reasonably logical explanation for what is happening here?
<< Previous
Bullboard Posts
Next >>